New Nordic | Active Liver Tablets | Pack of 2 x 30s

Product Information

DOACs pharmacokinetic properties (in particular liver metabolism of anti-Xa inhibitors) have raised concerns about potential drug induced liver injury (DILI) (i.e. transaminases > 3 × ULN with total bilirubin > 2 × ULN). Apart from Ximelagatran, an oral direct thrombin inhibitor which was rapidly withdrawn from the market in 2006 owing to a high risk of hepatoxicity, DOACs have generally demonstrated an adequate liver safety profile [ 5]. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.

If you have kidney disease, a cleanse that includes large amounts of juice can make your illness worse.

{{ filterOverlayFacet.displayName }}

Some companies use ingredients that could be harmful. Others have made false claims about how well they treat serious diseases. Gallagher C, Sanders P, Wong CX. Anticoagulation for atrial fibrillation in cirrhosis of the liver: are low-dose non-vitamin K oral anticoagulants a reasonable alternative to warfarin? J Am Heart Assoc. 2019;8:e012102.

Salem MB, et al. (2015). Pharmacologicalstudies of artichoke leaf extract and their health benefits. DOI: Anti-Xa levels are positively correlated with AT levels, which are reduced in cirrhotic patients [ 18, 20, 23, 24]. Therefore, the anti-Xa assay cannot be used to monitor AT-dependent anticoagulant drugs (LMWH/UFH) in patients with cirrhosis, given that it substantially underestimates drug levels. Conversely, the direct FXa and thrombin (FIIa) inhibitors can be monitored through the respective anti-Xa and anti-IIa assays in cirrhotic patients [ 19]. AF and VTE in Cirrhosis of Various Etiology Di Minno MN, Tufano A, Rusolillo A, Di Minno G, Tarantino G. High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol. 2010;16:6119–222.

Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis: possibilities and caveats. J Hepatol. 2013;59:358–66. Aside from DVT/PE, a major issue for patients affected by CLD is splanchnic vein thrombosis, including mesenteric, portal and hepatic vein thrombosis [ 32]. Portal vein thrombosis (PVT) is the most common VTE event in cirrhosis with a prevalence ranging from nearly 1% in compensated to 8–25% in decompensated cirrhosis [ 34, 35]. Mechanistic factors involved in the development of PVT in cirrhotic patients are likely to be multi-factorial. Prior VTE, thrombophilia, low portal vein flow velocity, malignancy, intra-abdominal infection, and recent surgery all increase the risk for PVT [ 32]. Of note, patients with cirrhosis who develop PVT and have no other history of clotting do not require a hypercoagulable workup [ 13]. The clinical presentation is variable and stability, regression, or resolution appear more common than clot progression [ 36]. Anticoagulation with LMWH appears safe and effective for PVT in cirrhosis [ 13, 37, 38]. AF and VTE in the NAFLD Spectrum If you are a healthy weight, it’s important to avoid gaining weight. This can make your NAFLD worse. Read more about keeping a healthy weight. Your doctor can advise you on types of activity that would suit you. Find out more about physical activity and exercise. Milk thistle extract (Silybum marianum, L.), globe artichoke extract (Cynara scolymus, L.), choline hydrogen tartrat, filling agent (microcrystalline cellulose), turmeric extract (Curcuma longa, L), disintegrator (crosslinked sodiumcarboxymethylcellulose), coating agents (vegetable magnesiumsalts of fatty acids, hydroxypropylmethyl cellulose, gum Arabic, talcum, glycerine), anti-caking agent (siliciumdioxide), modified potato starch.